Prophylaxis of posterior capsule opacification through autophagy activation with indomethacin-eluting intraocular lens
Bioactive Materials · 2023-05 · 23 · 539-550
DOI: 10.1016/j.bioactmat.2022.11.024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioactive Materials, 2023-05. Verfasst von Xiaobo Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Eye Center, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310009, PR China. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Research and Development Program of China, Fundamental Research Funds for the Central Universities, Shanxi Provincial Key Research and Development Project.
Abstract (Originalsprache)
Posterior capsule opacification (PCO) is the most common long-term postoperative complication of cataract surgery, leading to secondary vision loss. Optimized intraocular lens (IOL) structure and appropriate pharmacological intervention, which provides physical barriers and biological inhibition, respectively, can block the migration, proliferation, and epithelial-mesenchymal transition (EMT) of lens epithelial cells (LECs) for PCO prophylaxis. Herein, a novel indomethacin-eluting IOL (INDOM-IOL) with an optimized sharper edge and a sustained drug release behavior was developed for PCO prevention. Indomethacin (INDOM), an ophthalmic non-steroidal anti-inflammatory drug (NSAID) used for postoperative ocular inflammation, was demonstrated to not only be able to suppress cell migration and down-regulate the expression of cyclooxygenase-2 (COX-2) and EMT markers, including alpha-smooth muscle actin (α-SMA) and cyclin D1, but also promote the autophagy activation in LECs. Additionally, autophagy was also verified to be a potential therapeutic target for the down-regulation of EMT in LECs. The novel IOL, serving as a drug delivery platform, could carry an adjustable dose of hydrophobic indomethacin with sustained drug release ability for more than 28 days. In the rabbit PCO model, the indomethacin-eluting IOL showed excellent anti-inflammatory and anti-PCO effects. In summary, indomethacin is an effective pharmacological intervention in PCO prophylaxis, and the novel IOL we developed prevented PCO in vivo under its sustained indomethacin release property, which provided a promising approach for PCO prophylaxis in clinical application.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Eye Center, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310009, PR China.
- Zhejiang Provincial Key Lab of Ophthalmology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310009, PR China.
- MOE Key Laboratory of Macromolecule Synthesis and Functionalization of Ministry of Education, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou, 310027, PR China.
Förderung
- National Key Research and Development Program of China
- Fundamental Research Funds for the Central Universities
- Shanxi Provincial Key Research and Development Project
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
Zitieren
APA
Zhang, X., Wang, J., Xu, J., Xu, W., Zhang, Y., Luo, C., Ni, S., Han, H., Shentu, X., Ye, J., Ji, J., & Yao, K. (2023). Prophylaxis of posterior capsule opacification through autophagy activation with indomethacin-eluting intraocular lens. Bioactive Materials, 23, 539-550. https://doi.org/10.1016/j.bioactmat.2022.11.024
Vancouver
Zhang X, Wang J, Xu J, Xu W, Zhang Y, Luo C, et al. Prophylaxis of posterior capsule opacification through autophagy activation with indomethacin-eluting intraocular lens. Bioactive Materials. 2023;23:539-550. doi:10.1016/j.bioactmat.2022.11.024
BibTeX
@article{Zhang2023,
author = {Zhang, Xiaobo and Wang, Jing and Xu, Jingwei and Xu, Wen and Zhang, Yin and Luo, Chenqi and Ni, Shuang and Han, Haijie and Shentu, Xingchao and Ye, Juan and Ji, Jian and Yao, Ke},
title = {Prophylaxis of posterior capsule opacification through autophagy activation with indomethacin-eluting intraocular lens},
journal = {Bioactive Materials},
year = {2023},
volume = {23},
pages = {539--550},
doi = {10.1016/j.bioactmat.2022.11.024}
}
EUVIMED